Direct to consumer markets will fast track revenues with scripts available online so the narrative you're portraying is misrepresentative and the MCAP is $62m and not $125m as you quoted
There is plenty of pre-revenue biotech stocks trading at multiples of our current valuation as markets are forward looking, so if you've missed your chance on getting in on the prior two dips then I'm afraid I don't know what you are waiting for
Direct to consumer markets will fast track revenues with scripts...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add LTP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
88.0¢ |
Change
0.100(12.8%) |
Mkt cap ! $61.95M | |||
| Open | High | Low | Value | Volume |
| 78.5¢ | 97.5¢ | 78.0¢ | $643.5K | 743.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | 87.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 88.5¢ | 8422 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| LTP (ASX) Chart |